Search
Tynecon Receives Acceptance for Dinoprostone Tablets Registration and Marketing Authorization Application
2025-09-04 /
Read about 0 minute
Author：小编
Tynecon has announced that its wholly-owned subsidiary, Anhui Tynecon Pharmaceutical Co., Ltd., has recently received notification of acceptance from the National Medical Products Administration for its application to register and obtain marketing authorization for domestically produced Dinoprostone Tablets. Dinoprostone, a selective progesterone drug, is primarily used in the treatment of endometriosis. It effectively alleviates pain symptoms, stabilizes endometrial tissue, and is noted for its good tolerability and low incidence of adverse reactions.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
